Immunotherapy drug shows promise in fighting advanced throat cancer
NCT ID NCT05211232
First seen Jun 02, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This Phase 3 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after radiation therapy can improve outcomes for people with advanced nasopharyngeal cancer. About 450 participants are receiving either tislelizumab plus chemo or a placebo plus chemo. The study aims to see if the combination leads to complete tumor disappearance and longer survival without cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guizhou Cancer Hospital
Guiyang, Guizhou, China
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
The Affiliated Hospital of Guangdong Medical College
Zhanjiang, Guangdong, China
-
Wuzhou Red Cross Hospital
Wuzhou, Guangxi, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (an immunotherapy drug) combined with chemotherapy (gemcitabine and cisplatin)
What this could lead to
If successful, this could offer a more effective treatment approach for advanced nasopharyngeal cancer, potentially improving tumor shrinkage and delaying cancer progression.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet confirmed. Immunotherapy can cause immune-related side effects, and the added benefit over standard care is still uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.